Gene: MICAL2

9645
MICAL-2|MICAL2PV1|MICAL2PV2
microtubule associated monooxygenase, calponin and LIM domain containing 2
protein-coding
11p15.3
Ensembl:ENSG00000133816 MIM:608881 Vega:OTTHUMG00000165744 UniprotKB:O94851
NG_051801.1
SNP Mapped
2   ANCO-SNPs
ND
0   
NA (AD)  6.041e-1 (ND)   (Frontal_Cortex)
5.807e-1 (AD)  1.908e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs10831759chr11:12199835 (GRCh38.p7)A>Gnicotine dependenceSNV(Single Nucleotide Variation)
rs17477949chr11:12197656 (GRCh38.p7)C>Tnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KCNB10.968
SV2B0.964
SYT70.96
BSN0.96
TLN20.958
NPTX10.958
AP3B20.957
CLSTN30.957
AACS0.957
DNM10.956

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
YES1-0.59
HEY2-0.573
REST-0.567
MYL3-0.559
LRAT-0.554
WWTR1-0.553
RAI14-0.55
MBNL3-0.549
COPZ2-0.547
RNF135-0.54

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0284741,4-bis(2-(3,5-dichloropyridyloxy))benzene"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of MICAL2 mRNA"28903501
C5486512-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in decreased expression of MICAL2 mRNA19933214
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of MICAL2 mRNA"25510870
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of MICAL2 mRNA"19114083
C0142112,3,7,8-tetrachlorodibenzofuran"2,3,7,8-tetrachlorodibenzofuran results in decreased expression of MICAL2 mRNA"21724226
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of MICAL2 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of MICAL2 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of MICAL2 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of MICAL2 mRNA"25510870
C0144643,4-dichloroaniline"3,4-dichloroaniline results in increased expression of MICAL2 mRNA"24172598
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICAL2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICAL2 mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of MICAL2 mRNA22230336|2906747
D000082AcetaminophenAcetaminophen affects the expression of MICAL2 mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of MICAL2 mRNA22100608
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of MICAL2 mRNA19770486
D000393Air PollutantsAir Pollutants analog results in increased expression of MICAL2 mRNA21757418
D000535Aluminum[APP protein modified form binds to Aluminum] which results in increased expression of MICAL2 mRNA21298039
C547126AZM551248AZM551248 results in increased expression of MICAL2 mRNA22323515
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in decreased expression of MICAL2 mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MICAL2 mRNA21632981|2231617
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of MICAL2 mRNA19770486
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of MICAL2 mRNA22228805
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of MICAL2 mRNA"19150397|2623829
D004958EstradiolEstradiol results in increased expression of MICAL2 mRNA23019147|2686566
C006780bisphenol Abisphenol A affects the expression of MICAL2 mRNA25181051
C584509C646 compoundC646 compound results in decreased expression of MICAL2 mRNA26191083
D002220CarbamazepineCarbamazepine affects the expression of MICAL2 mRNA25979313
C523455CCG 1423CCG 1423 binds to and results in decreased activity of MICAL2 protein24440334
D002737ChloropreneChloroprene results in increased expression of MICAL2 mRNA23125180
C018021cobaltous chloridecobaltous chloride results in decreased expression of MICAL2 mRNA19320972
D019327Copper SulfateCopper Sulfate results in increased expression of MICAL2 mRNA19549813
D003471CuprizoneCuprizone results in increased expression of MICAL2 mRNA27523638
D016572CyclosporineCyclosporine results in increased expression of MICAL2 mRNA25562108
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of MICAL2 mRNA21266533
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of MICAL2 mRNA27392435
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of MICAL2 mRNA26865669
D004237DiuronDiuron metabolite results in increased expression of MICAL2 mRNA24172598
D004317DoxorubicinMICAL2 protein affects the susceptibility to Doxorubicin16217747
D004970EstroneEstrone results in increased expression of MICAL2 mRNA26865669
D008656MestranolMestranol results in increased expression of MICAL2 mRNA26865669
C024565ethylene dichlorideethylene dichloride results in increased expression of MICAL2 mRNA28189721
D005557FormaldehydeFormaldehyde results in decreased expression of MICAL2 mRNA20655997
D005557FormaldehydeFormaldehyde results in increased expression of MICAL2 mRNA23649840
C070081fulvestrantfulvestrant results in decreased expression of MICAL2 mRNA26865669
D019833GenisteinGenistein results in increased expression of MICAL2 mRNA26865669
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of MICAL2 mRNA20044591
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of MICAL2 mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of MICAL2 mRNA24796395
D007854LeadLead results in decreased expression of MICAL2 mRNA19921347
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 results in decreased expression of MICAL2 mRNA"24972896
D058185Magnetite Nanoparticles[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of MICAL2 mRNA26378955
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of MICAL2 mRNA23649840
C583365N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide"N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide results in decreased expression of MICAL2 mRNA"29244179
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of MICAL2 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of MICAL2 mRNA"25620056
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of MICAL2 mRNA"25510870
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of MICAL2 mRNA19710929
D011374ProgesteroneProgesterone results in decreased expression of MICAL2 mRNA23018184
D011374ProgesteroneProgesterone results in increased expression of MICAL2 mRNA23018184
D011374ProgesteroneProgesterone results in decreased expression of MICAL2 mRNA18070364
D011441PropylthiouracilPropylthiouracil results in decreased expression of MICAL2 mRNA24780913
D020849Raloxifene HydrochlorideRaloxifene Hydrochloride results in decreased expression of MICAL2 mRNA26865669
C009277sodium arsenatesodium arsenate results in decreased expression of MICAL2 mRNA21795629
C017947sodium arsenitesodium arsenite results in decreased expression of MICAL2 mRNA28595984
D004113Succimer[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of MICAL2 mRNA26378955
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of MICAL2 mRNA22903824
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MICAL2 mRNA21570461|2637764
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of MICAL2 mRNA19933214
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of MICAL2 mRNA26290441
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MICAL2 mRNA22298810
C009495titanium dioxidetitanium dioxide results in increased expression of MICAL2 mRNA23409001
C032910triadimefontriadimefon results in decreased expression of MICAL2 mRNA26705709
C012589trichostatin Atrichostatin A affects the expression of MICAL2 mRNA28542535
C013320tris(2-butoxyethyl) phosphatetris(2-butoxyethyl) phosphate affects the expression of MICAL2 mRNA29024780
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MICAL2 mRNA"27188386
D014635Valproic AcidValproic Acid results in increased expression of MICAL2 mRNA23179753|2438349
C025643vinclozolinvinclozolin affects the expression of MICAL2 mRNA19015723
D024483Vitamin K 3Vitamin K 3 affects the expression of MICAL2 mRNA20044591

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003779actin binding-IDA24440334  
GO:0003779actin binding-ISS-  
GO:0016491oxidoreductase activity-IDA24440334  
GO:0016709oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen-ISS-  
GO:0043914NADPH:sulfur oxidoreductase activity-IEA-  
GO:0046872metal ion binding-IEA-  
GO:0071949FAD binding-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0001947heart looping-ISS-  
GO:0007010cytoskeleton organization-IDA24440334  
GO:0007507heart development-ISS-  
GO:0010735positive regulation of transcription via serum response element binding-IMP24440334  
GO:0019417sulfur oxidation-ISS-  
GO:0030042actin filament depolymerization-IDA24440334  
GO:0030042actin filament depolymerization-ISS-  
GO:0055114oxidation-reduction process-IDA24440334  
GO:0055114oxidation-reduction process-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA24440334  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal